[Significance of combined arginine-betaine-sorbitol therapy in the treatment of metabolic liver diseases]

R Abbou, D Mahoudeau, J Dubrisay, M Volteau
La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris 1965 41(19):1170-1176

Bibliography

PubMed
PMID 4284191
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignIndexed case report; abstract unavailable
ModelHuman participants
SampleNot available in the indexed record
InterventionFormulation and dose require the original full report
DurationNot available in the indexed record
EndpointsHistorical or clinical context

What the study showed, in plain terms

Published in 1965, this source examined historical reports and formulation context. It is retained for source traceability. Abstract unavailable in PubMed and no accessible full report was verified for this summary. The paper title is not treated as sufficient evidence of efficacy, dose, safety or causality.

The indexed record verifies the publication and citation, but supplies no abstract. A quantitative effect or complete treatment result is not established from this record alone.

Abstract unavailable in PubMed and no accessible full report was verified for this summary. The paper title is not treated as sufficient evidence of efficacy, dose, safety or causality.

Continue with TMG Data Center

Continue with TMG Supplement: Trimethylglycine Benefits, Uses and Evidence

Key findings

  • The indexed record verifies the publication and citation, but supplies no abstract.
  • A quantitative effect or complete treatment result is not established from this record alone.
  • The recorded outcome domains were Historical or clinical context.

What this study can and cannot tell us

  • Abstract unavailable in PubMed and no accessible full report was verified for this summary. The paper title is not treated as sufficient evidence of efficacy, dose, safety or causality.
  • Source basis: Bibliographic data only; no abstract available. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial
Manal F Abdelmalek et al. · Hepatology (Baltimore, Md.) · 2009
Tier 2
Pilot trials of oral betaine in participants with metabolic dysfunction-associated steatotic liver disease and elevated alanine aminotransferase
Andrew S Lim et al. · Hepatology (Baltimore, Md.) · 2026
Tier 4
Betaine in Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanisms of Action and Therapeutic Potential
Tatjana Radosavljevic et al. · Antioxidants (Basel, Switzerland) · 2026
Tier 2
Metabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes
Ana Maria Grizales et al. · The Journal of clinical endocrinology and metabolism · 2018
Tier 4
Decoding Betaine: A Critical Analysis of Therapeutic Potential Compared with Marketing Hype-A Narrative Review
Grzegorz Nikrandt et al. · The Journal of nutrition · 2024
Tier 4
Betaine in human nutrition
Stuart A S Craig et al. · The American journal of clinical nutrition · 2004

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology